Cargando…

Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification

Luteolin, a natural flavone compound, exists in a variety of fruits and vegetables, and its anticancer effect has been shown in many studies. However, its use in glioma treatment is hampered due to the fact that the underlying mechanism of action has not been fully explored. Therefore, we elucidated...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Renxuan, Dong, Rui, Wang, Nan, Lan, Beiwu, Zhao, Hongyang, Gao, Yufei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643232/
https://www.ncbi.nlm.nih.gov/pubmed/34873410
http://dx.doi.org/10.1155/2021/7765658
_version_ 1784609841130504192
author Huang, Renxuan
Dong, Rui
Wang, Nan
Lan, Beiwu
Zhao, Hongyang
Gao, Yufei
author_facet Huang, Renxuan
Dong, Rui
Wang, Nan
Lan, Beiwu
Zhao, Hongyang
Gao, Yufei
author_sort Huang, Renxuan
collection PubMed
description Luteolin, a natural flavone compound, exists in a variety of fruits and vegetables, and its anticancer effect has been shown in many studies. However, its use in glioma treatment is hampered due to the fact that the underlying mechanism of action has not been fully explored. Therefore, we elucidated the potential antiglioma targets and pathways of luteolin systematically with the help of network pharmacology and molecular docking technology. The druggability of luteolin, including absorption, excretion, distribution, and metabolism, was assessed via the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The potential targets of luteolin and glioma were extracted from public databases, and the intersecting targets between luteolin and glioma were integrated and visualized by a Venn diagram. In addition, GO and KEGG pathway analysis was engaged in Metascape. The network of the luteolin-target-pathway was visualized by Cytoscape. Ultimately, the interactions between luteolin and predicted key targets were confirmed by Discovery studio software. According to the ADME results, luteolin shows great potential for development into a drug. 4860 glioma-associated targets and 280 targets of luteolin were identified, of which 205 were intersection targets. 6 core targets of luteolin against glioma, including AKT1, JUN, ALB, MAPK3, MAPK1, and TNF, were identified via PPI network analysis of which AKT1, JUN, ALB, MAPK1, and TNF harbor diagnostic value. The biological processes of luteolin are mainly involved in the response to inorganic substances, response to oxidative stress, and apoptotic signaling pathway. The essential pathways of luteolin against glioma involve pathways in cancer, the PI3K-Akt signaling pathway, the TNF signaling pathway, and more. Meanwhile, luteolin's interaction with six core targets was verified by molecular docking simulation and its antiglioma effect was verified by in vitro experiments. This study suggests that luteolin has a promising potential for development into a drug and, moreover, it displays preventive effects against glioma by targeting various genes and pathways.
format Online
Article
Text
id pubmed-8643232
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-86432322021-12-05 Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification Huang, Renxuan Dong, Rui Wang, Nan Lan, Beiwu Zhao, Hongyang Gao, Yufei Evid Based Complement Alternat Med Research Article Luteolin, a natural flavone compound, exists in a variety of fruits and vegetables, and its anticancer effect has been shown in many studies. However, its use in glioma treatment is hampered due to the fact that the underlying mechanism of action has not been fully explored. Therefore, we elucidated the potential antiglioma targets and pathways of luteolin systematically with the help of network pharmacology and molecular docking technology. The druggability of luteolin, including absorption, excretion, distribution, and metabolism, was assessed via the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). The potential targets of luteolin and glioma were extracted from public databases, and the intersecting targets between luteolin and glioma were integrated and visualized by a Venn diagram. In addition, GO and KEGG pathway analysis was engaged in Metascape. The network of the luteolin-target-pathway was visualized by Cytoscape. Ultimately, the interactions between luteolin and predicted key targets were confirmed by Discovery studio software. According to the ADME results, luteolin shows great potential for development into a drug. 4860 glioma-associated targets and 280 targets of luteolin were identified, of which 205 were intersection targets. 6 core targets of luteolin against glioma, including AKT1, JUN, ALB, MAPK3, MAPK1, and TNF, were identified via PPI network analysis of which AKT1, JUN, ALB, MAPK1, and TNF harbor diagnostic value. The biological processes of luteolin are mainly involved in the response to inorganic substances, response to oxidative stress, and apoptotic signaling pathway. The essential pathways of luteolin against glioma involve pathways in cancer, the PI3K-Akt signaling pathway, the TNF signaling pathway, and more. Meanwhile, luteolin's interaction with six core targets was verified by molecular docking simulation and its antiglioma effect was verified by in vitro experiments. This study suggests that luteolin has a promising potential for development into a drug and, moreover, it displays preventive effects against glioma by targeting various genes and pathways. Hindawi 2021-11-27 /pmc/articles/PMC8643232/ /pubmed/34873410 http://dx.doi.org/10.1155/2021/7765658 Text en Copyright © 2021 Renxuan Huang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Huang, Renxuan
Dong, Rui
Wang, Nan
Lan, Beiwu
Zhao, Hongyang
Gao, Yufei
Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification
title Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification
title_full Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification
title_fullStr Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification
title_full_unstemmed Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification
title_short Exploring the Antiglioma Mechanisms of Luteolin Based on Network Pharmacology and Experimental Verification
title_sort exploring the antiglioma mechanisms of luteolin based on network pharmacology and experimental verification
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643232/
https://www.ncbi.nlm.nih.gov/pubmed/34873410
http://dx.doi.org/10.1155/2021/7765658
work_keys_str_mv AT huangrenxuan exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification
AT dongrui exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification
AT wangnan exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification
AT lanbeiwu exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification
AT zhaohongyang exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification
AT gaoyufei exploringtheantigliomamechanismsofluteolinbasedonnetworkpharmacologyandexperimentalverification